We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
INOD Stock Expands GenAI Offerings: Can it Drive Enterprise Growth?
Read MoreHide Full Article
Key Takeaways
INOD secured $8M in new deals from four Big Tech clients in the reported quarter.
New GenAI tools, including a test platform built on NVIDIA tech, are driving enterprise demand for INOD.
DDS now contributes over 87% of total revenue, highlighting its central role in INOD's business.
Innodata (INOD - Free Report) is benefiting from the increasing demand for generative AI, fueling growth in its Digital Data Solutions (DDS) segment. DDS revenues reached $50.8 million in the first quarter of 2025, accounting for over 87% of total revenues. The growth was driven by client wins, deeper engagements with Big Tech and expanding use cases.
DDS delivers full-stack GenAI services, including training data creation, reinforcement learning and LLM evaluation. It supports industries such as enterprise tech, healthcare and cloud software, offering domain-specific capabilities across math, chemistry, Arabic and French. This vertical has emerged as a core driver of Innodata’s evolving AI service portfolio.
Momentum in INOD is being driven by the launch of the Generative AI Test & Evaluation Platform, which helps enterprises assess the safety and reliability of LLMs. Built on NVIDIA’s NIM microservices, it enables hallucination detection, adversarial prompt testing and risk benchmarking across formats. MasterClass has been the first charter customer. A broader launch is expected in the second half of 2025 through a global consulting partner.
Innodata is poised to benefit from the aggressive GenAI investments of the 'Magnificent 7,' with Microsoft committing $80 billion and Meta allocating $64-$72 billion for 2024. These tailwinds are expected to drive deeper enterprise engagements. INOD has secured $8 million in new deals from four Big Tech clients and signed a second statement of work with its largest customer, backed by a separate AI budget in the reported quarter. These developments position Innodata’s DDS for sustained momentum ahead.
Innodata Faces Competitive Pressure
Innodata’s DDS business is facing growing competition from TaskUs (TASK - Free Report) and Palantir Technologies (PLTR - Free Report) , both of which are advancing GenAI solutions.
TaskUs is scaling its offerings in model evaluation, data labeling and LLM safety testing, targeting industries like tech, healthcare and finance. Its focus on high-quality annotation and AI assurance tools makes TaskUs a strong competitor in INOD’s core markets.
Palantir is deepening traction with domain-specific LLM platforms and AI operating systems tailored for regulated sectors. Its enterprise deployments and decision-intelligence tools position Plantir to challenge INOD’s role as a GenAI enabler.
INOD’s Share Price Performance, Valuation and Estimates
Innodata stock is trading at a premium, with a forward 12-month Price/Sales of 5.98X compared with the industry’s 1.84X. INOD has a Value Score of F.
INOD’s Valuation
Image Source: Zacks Investment Research
The Zacks Consensus Estimate for Innodata’s 2025 earnings is pegged at 69 cents per share, unchanged over the past 30 days. The figure marks a decline of 22.47% from fiscal 2024’s earnings.
Image: Bigstock
INOD Stock Expands GenAI Offerings: Can it Drive Enterprise Growth?
Key Takeaways
Innodata (INOD - Free Report) is benefiting from the increasing demand for generative AI, fueling growth in its Digital Data Solutions (DDS) segment. DDS revenues reached $50.8 million in the first quarter of 2025, accounting for over 87% of total revenues. The growth was driven by client wins, deeper engagements with Big Tech and expanding use cases.
DDS delivers full-stack GenAI services, including training data creation, reinforcement learning and LLM evaluation. It supports industries such as enterprise tech, healthcare and cloud software, offering domain-specific capabilities across math, chemistry, Arabic and French. This vertical has emerged as a core driver of Innodata’s evolving AI service portfolio.
Momentum in INOD is being driven by the launch of the Generative AI Test & Evaluation Platform, which helps enterprises assess the safety and reliability of LLMs. Built on NVIDIA’s NIM microservices, it enables hallucination detection, adversarial prompt testing and risk benchmarking across formats. MasterClass has been the first charter customer. A broader launch is expected in the second half of 2025 through a global consulting partner.
Innodata is poised to benefit from the aggressive GenAI investments of the 'Magnificent 7,' with Microsoft committing $80 billion and Meta allocating $64-$72 billion for 2024. These tailwinds are expected to drive deeper enterprise engagements. INOD has secured $8 million in new deals from four Big Tech clients and signed a second statement of work with its largest customer, backed by a separate AI budget in the reported quarter. These developments position Innodata’s DDS for sustained momentum ahead.
Innodata Faces Competitive Pressure
Innodata’s DDS business is facing growing competition from TaskUs (TASK - Free Report) and Palantir Technologies (PLTR - Free Report) , both of which are advancing GenAI solutions.
TaskUs is scaling its offerings in model evaluation, data labeling and LLM safety testing, targeting industries like tech, healthcare and finance. Its focus on high-quality annotation and AI assurance tools makes TaskUs a strong competitor in INOD’s core markets.
Palantir is deepening traction with domain-specific LLM platforms and AI operating systems tailored for regulated sectors. Its enterprise deployments and decision-intelligence tools position Plantir to challenge INOD’s role as a GenAI enabler.
INOD’s Share Price Performance, Valuation and Estimates
INOD shares have jumped 29% year to date, while the broader Zacks Computer & Technology sector appreciated 8% and the Zacks Computer - Services industry grew 5.3%.
INOD’s Performance
Image Source: Zacks Investment Research
Innodata stock is trading at a premium, with a forward 12-month Price/Sales of 5.98X compared with the industry’s 1.84X. INOD has a Value Score of F.
INOD’s Valuation
Image Source: Zacks Investment Research
The Zacks Consensus Estimate for Innodata’s 2025 earnings is pegged at 69 cents per share, unchanged over the past 30 days. The figure marks a decline of 22.47% from fiscal 2024’s earnings.
Innodata Inc. Price and Consensus
Innodata Inc. price-consensus-chart | Innodata Inc. Quote
Innodata currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.